NEW YORK (GenomeWeb) – Qiagen and HTG Molecular Diagnostics have agreed to a second development program under their previously announced master assay development, commercialization, and manufacturing agreement.
Registering provides access to this and other free content.
Already have an account?Login Now.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.
This webinar will describe a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).
This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.
This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.
This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.